Impact of Serum Alpha-fetoprotein Levels on the Response to Direct Antiviral Therapy in Egyptian Patients With Chronic Hepatitis C
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- Number of patients with sustained virologic response
研究概览
简要总结
Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C
详细描述
Impact of Serum Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Egyptian Patients with Chronic Hepatitis C
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HCV patients who will undergo treatment by direct acting antiviral agents.
排除标准
- •Patients with decompensated liver disease
研究组 & 干预措施
Normal Alfafetoprotein
Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
干预措施: Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir (Drug)
Mild elevation of alfafetoprotein
Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
干预措施: Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir (Drug)
High elevation of alfafetoprotein
Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
干预措施: Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir (Drug)
结局指标
主要结局
Number of patients with sustained virologic response
时间窗: 6 months
The total number of patients with SVR in each group
次要结局
未报告次要终点
研究者
Sherief Abd-Elsalam
PhDTropical Medicine
Tanta University